Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,126 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.9% Normal Saline Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Propranolol Rescue of Prolonged Labor

NCT04299438
View directory record Official record
Conditions
Pregnancy, Prolonged
Interventions
Propranolol Hydrochloride, Saline
Drug · Other
Lead sponsor
Lisa Levine
Other
Eligibility
16 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 14, 2026, 2:05 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

NCT00801138
View directory record Official record
Conditions
Anesthesia, Local, Shoulder Surgery
Interventions
saline, Dexamethasone, ropivacaine, Bupivacaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

NCT04026321
View directory record Official record
Conditions
Solid Tumor Refractory to Standard Therapy
Interventions
SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%
Drug
Lead sponsor
Livzon Pharmaceutical Group Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 14, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

NCT05570448
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
ARAT, Sham intervention (control)
Procedure
Lead sponsor
Midwest Veterans' Biomedical Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 14, 2026, 2:05 PM EDT
Recruiting Early Phase 1 Interventional

TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study

NCT06580509
View directory record Official record
Conditions
Hemorrhage, Surgical, Tonsillar Bleeding
Interventions
Tranexamic Acid Injectable Product, Normal Saline
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
View directory record Official record
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

NCT00005908
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 14, 2026, 2:05 PM EDT
Not listed Phase 1 Interventional

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

NCT03908840
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TBI 302
Biological
Lead sponsor
Evolve Biologics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

NCT01126593
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
0.5% bupivacaine, Normal Saline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Growth Hormone Administration and the Human Immune System

NCT00663611
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Norditropin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
25 Years to 50 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 14, 2026, 2:05 PM EDT
Not listed Phase 2 Interventional

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050
View directory record Official record
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 14, 2026, 2:05 PM EDT
Recruiting Phase 2 Interventional

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

NCT04647240
View directory record Official record
Conditions
Venous Stasis Ulcer, Venous Leg Ulcer
Interventions
MTX-001 (human amniotic fluid)
Biological
Lead sponsor
Merakris Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Tucson, Arizona • Castro Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 14, 2026, 2:05 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability Study With Bexagliflozin

NCT03417076
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Thiamine as a Renal Protective Agent in Septic Shock

NCT03550794
View directory record Official record
Conditions
Sepsis, Kidney Injury, Thiamine Deficiency
Interventions
Thiamine Hydrochloride, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022
View directory record Official record
Conditions
Healthy
Interventions
Clinical Center Reference Endotoxin (CCRE), Normal saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2Phase 3 Interventional

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

NCT04428372
View directory record Official record
Conditions
Hemodialysis Complication, Hemodynamic Instability
Interventions
Mannitol, 0.9% saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 14, 2026, 2:05 PM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01371305
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 84 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 14, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 14, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 14, 2026, 2:05 PM EDT